Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

HeartBeam, Inc. BEATW NASDAQ

NASDAQ Capital Marke • Healthcare • Medical - Healthcare Information Services • US • USD

SharesGrow Score
44/100
2/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

HeartBeam, Inc. (BEATW) is a Medical - Healthcare Information Services company in the Healthcare sector, currently trading at $0.12. It has a SharesGrow Score of 41/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Valuation: BEATW trades at a trailing Price-to-Earnings (P/E) of -1.9 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.11.

Net income is $21M (loss), growing at -17.9%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $0 against $3M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 1.45 (adequate). Debt-to-assets is 0%. Total assets: $6M.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 75/100 (Pass), Moat 28/100 (Fail), Future ?/100 (Fail), Income ?/100 (Fail).

BEATW SharesGrow Score Overview

55/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 75/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 28/100
Gross margin is + market cap
FUTURE 0/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — BEATW

✓
VALUE Pass
100/100
BEATW trades at a trailing Price-to-Earnings (P/E) of -1.9 (S&P 500 average ~25). Forward PEG 0.11 — Peter Lynch undervalued (≤1.0). Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
BEATW: +0%/yr revenue is, -17.9%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
75/100
Balance sheet BEATW: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is 1.45 (adequate). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
28/100
BEATW: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.
View details →
—
FUTURE N/A
N/A
No analyst coverage available for this stock.
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range0.12-0.2899
Volume2.8K
Avg Volume (30D)12.86K
Market Cap$4.07M
Beta (1Y)1.09
Share Statistics
EPS (TTM)-0.62
Shares Outstanding$33.71M
IPO Date2021-11-11
Employees15
CEOBranislav Vajdic
Financial Highlights & Ratios
Gross Profit$-40K
EBITDA$-21.14M
Net Income$-21.02M
Operating Income$-21.14M
Total Cash$4.38M
Net Debt$-4.38M
Total Assets$5.84M
Price / Earnings (P/E)-0.2
Analyst Forecast
Company Info
CountryUS
ExchangeNASDAQ Capital Marke
CurrencyUSD
ISINUS42238H1169

Price Chart

Track all markets on TradingView
BEATW
HeartBeam, Inc. ↗  ·  NASDAQ Capital Marke
Healthcare • Medical - Healthcare Information Services
0.12 52WK RANGE 0.29

People Also View

AUGX
AUGX
Augmedix, Inc.
$2.35
-0.21%
 BFRIW
BFRIW
Biofrontera Inc.
$0.03
-14.53%
 ISPOW
ISPOW
Inspirato Incorporated
$0.01
+2.86%
 DRMAW
DRMAW
Dermata Therapeutics, Inc.
$0.01
-22.91%
 BCTXW
BCTXW
BriaCell Therapeutics Corp.
$0.00
0.00%
 LLY
LLY
Eli Lilly and Company
$905.13
-1.88%
 JNJ
JNJ
Johnson & Johnson
$238.67
-0.60%
 ABBV
ABBV
AbbVie Inc.
$208.43
-0.87%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message